Xin Lang Cai Jing·2026-02-06 07:56Core Viewpoint - WuXi AppTec is a leading international open-access capability and technology platform providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2]. Group 1: Company Overview - WuXi AppTec is a domestic leader in the pharmaceutical outsourcing industry and one of the earliest companies engaged in integrated CRO (Contract Research Organization) and CMO (Contract Manufacturing Organization) services [2]. - The company has a high-level management team with over 200 authorized and pending patent achievements [2]. - Its main business involves the discovery, research, and production of small molecule chemical drugs, offering a full range of integrated platform services to global pharmaceutical companies [2][7]. Group 2: Financial Performance - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61% [7]. - The net profit attributable to the parent company was 12.076 billion yuan, showing a significant year-on-year increase of 84.84% [7]. - The company has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [8]. Group 3: Market Position and Trends - As of February 6, the stock price of WuXi AppTec increased by 0.74%, with a trading volume of 3.438 billion yuan and a turnover rate of 1.42%, leading to a total market capitalization of 291.901 billion yuan [1]. - The company benefits from a high overseas revenue ratio of 78.67%, which is positively impacted by the depreciation of the Chinese yuan [3]. - The average trading cost of the stock is 97.44 yuan, with the stock price approaching a resistance level of 98.02 yuan, indicating potential for upward movement if this level is surpassed [6].